ONCOLYTICS BIOTECH INC (ONCY)
CA6823108759 - Common Stock
Taking everything into account, ONCY scores 1 out of 10 in our fundamental rating. ONCY was compared to 568 industry peers in the Biotechnology industry. ONCY may be in some trouble as it scores bad on both profitability and health. ONCY has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ONCY had negative earnings in the past year.
In the past year ONCY has reported a negative cash flow from operations.
In the past 5 years ONCY always reported negative net income.
ONCY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -113.93%, ONCY is doing worse than 78.94% of the companies in the same industry.
With a Return On Equity value of -305.20%, ONCY is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.93% | ||
| ROE | -305.2% | ||
| ROIC | N/A |
ROA(3y)-63.13%
ROA(5y)-94.49%
ROE(3y)-85.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ONCY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ONCY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ONCY has been increased compared to 5 years ago.
ONCY has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -27.53, we must say that ONCY is in the distress zone and has some risk of bankruptcy.
ONCY's Altman-Z score of -27.53 is on the low side compared to the rest of the industry. ONCY is outperformed by 90.27% of its industry peers.
ONCY has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, ONCY is not doing good in the industry: 64.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -27.53 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.99 indicates that ONCY has no problem at all paying its short term obligations.
ONCY's Current ratio of 2.99 is on the low side compared to the rest of the industry. ONCY is outperformed by 65.13% of its industry peers.
A Quick Ratio of 2.99 indicates that ONCY has no problem at all paying its short term obligations.
ONCY has a Quick ratio of 2.99. This is in the lower half of the industry: ONCY underperforms 62.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
ONCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.41%, which is quite impressive.
EPS 1Y (TTM)29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ONCY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.66% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-15.99%
EPS Next 2Y0.92%
EPS Next 3Y-3.24%
EPS Next 5Y8.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ONCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ONCY's earnings are expected to decrease with -3.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.92%
EPS Next 3Y-3.24%
5. Dividend
5.1 Amount
ONCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCOLYTICS BIOTECH INC
NASDAQ:ONCY (12/20/2024, 8:00:02 PM)
After market: 0.8297 0 (-0.16%)0.831
-0.06 (-6.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.69%
Inst Owner Change-3.37%
Ins Owners3.58%
Ins Owner ChangeN/A
Market Cap64.05M
Analysts80
Price Target4.6 (453.55%)
Short Float %3.09%
Short Ratio4.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.12%
Min EPS beat(2)-15.35%
Max EPS beat(2)3.1%
EPS beat(4)3
Avg EPS beat(4)17.91%
Min EPS beat(4)-15.35%
Max EPS beat(4)66.41%
EPS beat(8)4
Avg EPS beat(8)0.65%
EPS beat(12)7
Avg EPS beat(12)4.92%
EPS beat(16)9
Avg EPS beat(16)4.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.61%
PT rev (3m)-8.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.17 | ||
| P/tB | 10.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.93% | ||
| ROE | -305.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-63.13%
ROA(5y)-94.49%
ROE(3y)-85.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 53.85% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | -27.53 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)28.83%
Cap/Depr(5y)39.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-15.99%
EPS Next 2Y0.92%
EPS Next 3Y-3.24%
EPS Next 5Y8.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-44.54%
EBIT Next 3Y-32.64%
EBIT Next 5Y-4.24%
FCF growth 1Y-15.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.66%
OCF growth 3YN/A
OCF growth 5YN/A